Tissue nosode, preparation for treating bovine mastitis and method for using it

FIELD: medicine.

SUBSTANCE: group of inventions refers to veterinary science and is applicable for treating bovine mastitis. What is declared is a nosode for producing a preparation for treating bovine mastitis. That involves taking mastitis milk 1 ml with clinical signs of purulent-catarrhal mastitis, filling it 70° alcohol 9 ml to produce a homogenous solution; the produced solution is diluted to "Д6" with 70° alcohol. What is also declared is a preparation for treating bovine mastitis containing an aqueous-alcoholic solution of components. The components are Belladonna, Sulphur, Apis mellifica, Conium, Phytolacca, Silicea and above nosode in the following proportions, wt %: Belladonna - 5, Sulphur - 20, Apis mellifica - 20, Conium - 10, Phytolacca - 10, Silicea - 5, nosode - 15, aqueous-alcoholic solution up to 100%. What is also declared is a method of treating bovine mastitis involving the intracisternal administration of the preparation. The preparation is administered in a dose of 5-10 ml per 1 animal once a day.

EFFECT: declared group of inventions is highly effective in treating bovine mastitis.

3 cl, 5 tbl, 1 ex

 

The invention relates to veterinary, in particular to means and methods for treating mastitis in cattle.

Known antibacterial drugs for the treatment of mastitis - penicillin, tetracycline, oxytetracycline, neomycin, masterid, mastison A, B, E and others (Worms D. K. et al. Drugs in veterinary medicine. - M.: Kolos 1977. - Pp. 290-325), which have antibacterial General and local activity against the infectious agent of the udder. The drugs are based on the destruction of a wall of a microorganism or inhibiting the protein-synthesizing processes in DNA and RNA in the cell of the pathogen of infectious mastitis.

The use of antibiotic drugs for the treatment of lactating cows due to their frequent use (treatment - 3-5 injections) leads to development of resistant races of microorganisms, which significantly reduces the effectiveness of treatment and increases the risk of mastitis and atrophy of the affected quarters of the udder. Increasing the concentration of antibiotics in the preparations, in order to increase the effectiveness of treatment leads to increase in terms of rejection of milk from cows after treatment.

The closest solution adopted for the prototype, is Neotel is an antibacterial drug with a combination of two antibiotics (neomycin, tilan, oil base), which gumulira�tsya in the tissues for a long time and is eliminated from the body, slowly relieves inflammation and restores the function of the breast. In addition, the milk in the application of this drug unsuitable for food purposes within 4-6 days after the end of treatment (S. M. Navashin, I. P. Fomin. Rational antibiotic therapy. - M.: Medicine, 1982. - P. 233-236).

The objective of the claimed solution is the extension of Arsenal of means for treatment of mastitis in cattle and reduction of terms of treatment of sick animals.

The problem is solved in that in the nosode for the preparation of a drug for treatment of mastitis in cattle, according to the invention, take 1 ml of milk with mastitis clinical signs of purulent-catarrhal mastitis, which pour 9 ml of 70° alcohol to obtain a homogeneous solution, after which the resulting solution is diluted to a dilution D6 70° alcohol.

The problem is solved in that in the preparation for the treatment of mastitis in cattle, comprising an aqueous-alcohol solution components according to the invention, as components used Belladonna, Sulfur, Apis mellifica, Conium, Phytolacca, Silicea and nosode in the following ratio of components, mass. %: Belladonna - 5, Sulfur - 20, Apis mellifica - 20, Conium - 10, Phytolacca - 10, Silicea - 5, nosode - 15, water-alcohol solution to 100%.

The problem is solved also by the fact that in the method of treatment of mastitis cattle�about cattle, including intracisternally the introduction of the drug, according to the invention, the drug is administered according to claim 2 in a dose of 5-10 ml of 1 animal, 1 times a day.

The proposed drug acts locally, restores the metabolism, stimulates the immune system, affects the Central nervous system that leads to a cascade of biological responses at the molecular and submolecular levels in the cells of the body, leading to reparative, regenerative processes. In the preparation includes the components in a low dilution in the content of active substance from 10-6up to 10-200g/ml or more.

Nosodes are homeopathic medicines derived from cultures of microorganisms, viruses, tissues, organs, secrets or abnormal excreta (Julian Otto-andré. Materia Medica of the nosodes. TRANS.with it. M.: Arnebia, 2003. - C. 5, 14, 15).

The nosode for the preparation of a drug for treatment of mastitis in cattle, which is prepared as follows: take 1 ml of milk with mastitis clinical signs of purulent-catarrhal mastitis, which pour 9 ml of 70° alcohol to obtain a homogeneous solution, after which the resulting solution is diluted to a dilution D6 70° alcohol.

The highest therapeutic effect of the dilution of the nosode D6, which is used for preparation of drug Krasnik I. �farmacevticheskaja homeopathy: Proc. the Handbook for students. the high. proc. institutions / I. I. Krasnykh, G. V. Mikhailov, edited by N. And. Zamaraeva. - M.: Publishing center "Academy", 2005. - P. 42).

Justification of the most spectacular breeding nosode for example OS neutrophils of cattle.

Evaluation of the effect of homeopathic medicines on opsonophagocytic response (GSR) of neutrophils of cattle using the methodology described Smirnov P. N. (2003), including study phagocytose activity of neutrophils (FA), phagocytic number (FC), phagocytic index (PI) and phagocytic capacity (FE) digesting the blood's ability (UCS).

To determine the effect of nosode on OS neutrophils of cattle were chosen different dilutions of the nosode. In the experiments used Pharmacopoeia denote substances used in very low concentrations: Dl - 10-1g/ml; D2 - 10-2; D3 - 10-3; D4 - 10-4; D5 - 10-5; D6 - 10-6; D7 - 10-7; D8 - 10-8; D9 - 10-9, D10-10-10g/ml to study the influence of nosode on the functional activity of quantitative and qualitative indicators of OS neutrophils, we defined a multi-dimensional effect depending on the degree of cultivation (tab. 1).

In studying the effect of homeopathic medicines on the functional activity of neutrophils installed Bo�its pronounced activation quantitative (FA, FE), quality (FI, FC) characteristics of nosode D6. So, with the nosode in breeding D6 set to the maximum growth: FA was 91%, FE 45%, FI - 78%, FC - 59%, UCS - 36%.

The drug is prepared as follows: sterile distilled water to 1 liter add: 1 part Belladonna, 2 parts Sulfur, 2 parts Apis mellifica, 1.5 parts of Conium, 1 part Phytolacca, 1 part Silicea and 1.5 parts of nosode D6.

The above components of the drug (Belladonna, Sulfur, Apis mellifica, Conium, Phytolacca, Silicea and nosode D6) is introduced into 15 ml of 70° alcohol and shaken vigorously for 10-15 times, then poured into a container with 1 l of distilled water and again shaken vigorously for 3-5 minutes. The resulting solution is poured, sealed and labeled.

The drug in a volume of 100 ml is stored at a temperature of 10-20°C for 1 year. The proposed drug has the name of Mastiha. Substantiation of the drug on the example of the effect of substances in very low concentrations on OS neutrophils of cattle.

To determine the effect of drugs ultra low dilutions on OS neutrophils of cattle were selected drugs used in homeopathic practice of treatment that correspond to the clinical symptoms of the disease.

Were used for research of the finished form of medicinal substances in the form of homeopathic grains (GOST 7060-79), p�izvodstvo LLC GMC", Novosibirsk. In the experiments used Pharmacopoeia denote substances used in very low concentrations: D6 - 10-6g/ml; C6 - 10-12; C12 - 10-24; C30 - 10-60; C200 - 10-400g/ml.

In studying the effect of homeopathic medicines on the functional activity of quantitative and qualitative indicators of OS neutrophils, we defined a multi-dimensional effect depending on the degree of cultivation and type of drug (table. 2).

In studying the effect of homeopathic medicines on the functional activity of neutrophils installed more pronounced activation of the quantitative (FA, FE), quality (FI, FC) characteristics and UCS, accompanied by the maximum growth of Phytolacca 12, Belladonna C12, sulphur C200, APIs C12, Conium C30, C30 Silicon and nosode D6.

Study of the effect of homeopathic substances on OS of blood neutrophils showed that maximal activation of cellular immunity was observed after exposure of neutrophils complex drug Mastitis, characterized by a rise in F - 641,8%, FE - 560,3%, the CLAIM - 530,1%, FC - 489,3%, FI - 340,6%.

Determination of the optimal therapeutic dose

To determine the optimal therapeutic dose of the drug Mastiha on the principle of analogues were formed fifteen groupcare, patients with subclinical and serous mastitis (table.3). Animals were injected intracisternally Mastiha, 1-15 ml, 1 times a day depending on the group. The results showed that the most effective dose of the drug, has a pronounced therapeutic effect and a shorter duration of treatment (2,7 ą 1.3 and 3.2±1,4 days), dose is 5-10 ml in groups No. 5-10.

The invention is illustrated by the following examples. To study therapeutic efficacy of treatment of mastitis of cows, on the principle of analogues were formed four groups of animals (two groups of 25 goal. diagnosed with subclinical mastitis and two groups of 70 goal. a diagnosis of serous mastitis). The cows of the control group with a diagnosis of subclinical mastitis (n=25) was administered to Neotel intracisternal 5 ml, 1-2 times a day. Animals of the experimental group, with the same diagnosis (n=25) were injected intracisternally Mastiha 5-10 ml, 1 time per day. In the control group of cows with serous mastitis (n=70) intracisternal introduced Neotel 5 ml, 1-2 times a day, while the animals of the experimental group with the same diagnosis (n=70) were injected with Mastiha intracisternal, 5-10 ml, 1 time per day.

Positive changes in clinical condition of the animals treated with the drug Mastiha, subclinical and serous mastitis, were noted on the second day, and 72% and 2.4% of animals with�Testino, while in groups, which used the drug Neotel positive results on the second day, received only 16% and 0.4% respectively. Recovery of cows with subclinical and serous mastitis, in the treatment of drug Mastiha occurred within an average of 2.7 ą 1.3 and 3.2±1.4 days, and in the treatment of drug Neotel - 4,5±1,9 and 6.2±2.5 days, respectively. During production experiments in the control group of cows with serous mastitis treatment resulted in an abscess of the udder has 7 goals (10%) and culling 4 goals (5,7%) (tab. 4).

After treatment of cows with subclinical and serous mastitis in the control group was diagnosed with a relapse in 3 animals (12%) and 11 animals (15,7%), respectively. In the experimental group cases of recurrence were noted in the treatment of serous mastitis in 2.8% of animals. Recovery of cows with subclinical and serous mastitis, after relapse in the treatment of drug Mastiha occurred within an average of 2.5+0.5, and the preparation of Neotel 4,6±0,4 and 5.4±0.6 days, respectively (tab. 5).

Economic effectiveness of veterinary interventions in the treatment of subclinical and serous mastitis on 1 rbl. of cost of drug Neotel have had negative values (-0.3 and -7,7 rubles), while using the drug Mastiha the received e�economic effect on 1 RUB. cost of 17.5 14.3 RUB RUB respectively.

1. The nosode for the preparation of a drug for treatment of mastitis in cattle, characterized in that the take 1 ml of milk with mastitis clinical signs of purulent-catarrhal mastitis, which pour 9 ml of 70° alcohol to obtain a homogeneous solution, after which the resulting solution is diluted to a dilution D6 70° alcohol.

2. Drug for treatment of mastitis in cattle, comprising an aqueous-alcohol solution of the components, characterized in that the components used Belladonna, Sulfur, Apis mellifica, Conium, Phytolacca, Silicea and nosode according to claim l, with the following ratio of components, wt.%:

Belladonna5
Sulfur20
Apis mellifica20
Conium10
Phytolacca10
Silicea5
Nosode1-15
Water-alcohol solutionto 100%

3. A method for the treatment of mastitis in cattle, including intracisternally up�to the amount of the drug, characterized in that the administered drug according to claim 2, in a dose of 5-10 ml per 1 animal 1 per day.



 

Same patents:

Antimicrobial agent // 2556509

FIELD: medicine.

SUBSTANCE: compound 2-(1'-hydroxy-4'-isopropenyl-1'-methylcyclohexyl-2'-thio)-methylethanoate having structural formula I: is applicable as an antimicrobial agent.

EFFECT: using the compound of formula I possessing antimicrobial activity provides treating infectious processes caused by susceptible organisms.

5 tbl

FIELD: medicine.

SUBSTANCE: claimed group of inventions relates to field of veterinary. Claimed are: vaccine, aimed against actinobacillous pleuropneumonia, including lipopolysaccharide in complex with one or more repeats of ApxI, ApxII and ApxIII toxins, separated from bacterial culture and polymyxin to reduce symptoms of endotoxic shock, caused by lipopolysaccharide, method of obtaining such vaccine, application of polymyxin to reduce endotoxic shock symptoms when vaccine is introduced, in which polymixyn is added into vaccine in dose from 2.6 to 60 mcg/ml.

EFFECT: claimed group of inventions provides effective means and methods to reduce endotoxic shock symptoms, caused by lipopolysaccharide, when vaccine against actinobacillous pleuropneumonia is introduced to animal.

14 cl, 4 tbl, 4 ex

FIELD: veterinary medicine.

SUBSTANCE: complex antibacterial agent for animals, containing a compound from the group of fluoroquinolones and auxiliary substances, characterised in that it additionally comprises a compound from the group of pleuromutilins in an effective amount.

EFFECT: invention is effective against vegetative and spore forms of bacteria, it is harmless, has no allergenic properties, has a stimulating effect on the indices of humoral immune response, and is stable during storage.

6 cl, 9 ex

FIELD: veterinary medicine.

SUBSTANCE: agent comprises enrofloxacin and excipients. The agent additionally comprises humates of peat or sapropel, with the following ratio of the components, wt %: enrofloxacin substance - 0.5; alkaline solution of humates (pH=12-13) - 80; succinic acid - to pH 10-11; propylene glycol - the rest. The agent is administered with the liquid feed once a day for three to five days at a dose of from 0.5 to 1.0 ml per 1 kg of body weight.

EFFECT: manifestation of pronounced therapeutic effect.

5 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of obtaining 7-hydroxyroyleanon, possessing antimicrobial action. said method includes extraction of crushed roots of salvia officinalis with 96% ethyl alcohol with further extract evaporation, processing with water, alcohol distillation and processing with hydrophobic solvent or extraction of said raw material with chloroform with further extract processing with water and evaporation; after which target product is extracted from organic phase by transfer into water-soluble phenolates, with processing with sodium hydroxide water solution; alkali solution is washed with chloroform; acidified with hydrochloric or sulphuric acid; obtained sediment is filtered; dried and crushed.

EFFECT: invention is characterised by improved process manufacturability and provides obtaining individual substance with higher antimicrobial activity than previously extracted royleanon derivatives from salvia officinalis.

2 tbl, 6 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to a strain of the pathogen of pseudomonosis of pigs of the collection of Federal state budgetary institution "VGNKI", deposited under the name "Pseudomonas aeruginosa No.9" and the registration number "No.9-DEP", intended for production of a vaccine against pseudomonosis of pigs.

EFFECT: invention provides high immunogenic activity and the ability of production of the vaccine against pseudomonosis of pigs.

4 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to clinical microbiology and antimicrobial chemotherapy, and concerns developing and creating new combinations providing potentiating bactericidal action and effectively inhibiting the purulent infection caused by methicillin-resistant S. aureus by using two classes of compounds possessing the essentially different mechanism of antimicrobial action.

EFFECT: developing and creating the new combinations providing potentiating bactericidal action and effectively inhibiting the purulent infection.

2 dwg, 6 tbl

FIELD: medicine.

SUBSTANCE: drops possessing antiviral and immunomodulatory effects characterised by the fact that they represent a 95% ethanol infusion of wild strawberry leaves and fruit specified in: red raspberry fruit, mountain ash fruit, bilberry fruit, blood-red hawthorn fruit, cinnamon rose fruit; 15-25 mg of the substance in 1 ml of the infusion.

EFFECT: drops possess pronounced antiviral and immunomodulatory effects.

15 tbl, 5 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to polymer ketimine derivatives of doxycycline, which are obtained by condensation of doxycycline hydrochloride with cationic copolymers of acrylamide with 2-ammine-ethyl methacrylate (MW=16-20 kDa) with a molar ratio of copolymer/antibiotic equal to 1.1-2.0/1 in aqueous solution with pH 8.0 at 23°C. where: m=(78.0-80.0) mol %; n=(10.0-14.0) mol.%; k=(6.0-12.0) mol %.

EFFECT: polymer ketimine derivatives of doxycycline, which are non-toxic and combine the antimicrobial and immunosuppressive properties.

2 cl, 1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a peptide, a peptide mimetic or an amino acid derivative, which contain di-substituted β-amino acid, wherein each of substituting group in the β-amino acid, which can be identical or different, contains at least 7 non-hydrogen atoms, is lipophilic and contains at least one cyclic group; one or more cyclic groups in the substituting group can be bound or condensed with one or more numbers of cyclic groups in the other substituting groups, and when the cyclic groups are fused so that an aggregate total number of non-hydrogen atoms for these two substituting groups makes at least 12, wherein the above peptide, peptide mimetic or amino acid derivative consist of 1-4 amino acids or length-equivalent sub-units.

EFFECT: preparing the peptide, peptide mimetic or amino acid derivative, which contain the di-substituted β-amino acid.

17 cl, 4 dwg, 10 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical composition, containing compound of formula or for prevention or treatment of diseases, associated with oxidative stress, selected from group, consisting of MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke episodes), MERRF syndrome (myoclonic epilepsy with ragged red fibres) or Kearns-Sayre syndrome, arrhythmia, cardioplegia or myocardium infarction. in formula (1) na stands for 1 or 2, Aa represents 5-membered heteroaryl or heterocycle, each of which has 2 heteroatoms, selected from N, O and S, Rla represents R5a-Xa-Ba-X′a-, Ba represents direct bond, Xa and X′a independently on each other represent direct bond or -OC(O)-, R5a represents hydrogen or 6-9-membered monocyclic or condensed cyclic heterocycle or heteroaryl, each of which has from 1 to 3 heteroatoms, selected from N, O and S, and is optionally substituted with oxo or C1-C6-alkyl, R2a represents -(CR8aR9a)pa-Ya-R7a, pa stands for number from 0 or 1, Ya represents direct bond or -O-, R7a represents hydrogen or phenyl, R3a, R8a, R9a, R10a represent hydrogen, R4a represents -(CH2)pa-Da-R10a-, Da represents C5-cycloalkyl or 6-membered heterocycle, which has 1 heteroatom, selected from N, S and O. Radical values for formula (2) are give in invention formula.

EFFECT: obtaining compositions for prevention or treatment of diseases, associated with oxidative stress.

19 dwg, 5 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: opening of a carious cavity, ablation of overhanging enamel edges on the entire circumference, necrectomy and drug treatment with a 0.06% chlorhexidine solution are performed. The preparation "Lemifaren" is applied on walls and bottom of the carious cavity in a uniform 1 mm thick layer, which is left for 1 day under temporary filling. After the removal of the preparation irradiation in a pulse mode with the power of 5 W and frequency of 2000-3000 Hz is carried out for 5 min with the application of the laser apparatus ALST-01. After that, the cavity is restored with an account of functional and aesthetic parameters of the particular tooth.

EFFECT: effective treatment of deep caries prevents caries recurrences and pulp inflammation.

1 ex

FIELD: medicine.

SUBSTANCE: method involves administering an anthelminthic agent in the period of stationary process stage; the anthelminthic treatment is preceded by administering chophytol 200 mg 3 times a day before meals for 14 days; the anthelminthic treatment involves administering Osinol food supplement 2 tablets 3 times a day during meals for 14 days; thereafter, chophytol is taken in a dose of 200 mg 3 times a day before meals for 14 days; 7 days later, the repeated course of the anthelminthic treatment with Osinol food supplement 2 tablets 3 times a day during meals is prescribed to be administered for 14 days; the entire therapeutic course involves washing the face with the Setaphyldermocontrol foaming facial cleanser 2 times a day followed by applying an SPF30 product on the face once after the morning wash.

EFFECT: reducing the number of complications and the high efficacy of the anthelminthic treatment.

1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to cosmetic industry and provides a composition for depositing on keratin surfaces, which contains composition particles in the form of fused agglomerates having a part containing at least one dye and a part containing at least one transparent and translucent thermoplastic material, where the composition particles contain, based on the weight of all of the powdered composition material, about 10 to 90 parts of the dye part and about 90 to 10 parts of the transparent and translucent thermoplastic material part, and a method of producing the powdered composition material.

EFFECT: invention enables to obtain cosmetic compositions which will have an improved outer appearance on the skin and fewer SKU.

23 cl, 10 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and is intended for oral cavity care. Compositions contain: a) guanidine-based active substance, b) film-forming polymer, c) hydrophobic modifier of viscosity in quantity, sufficient for provision of composition for oral cavity care with time particle sedimentation more than 20 minutes, and d) oil carrier. Guanidine-based active substance preferably represents L-arginine. Film-forming polymer preferably represented GANTREZ. Hydrophobic modifier of viscosity preferably represents thickened mineral oil. Oil carrier preferably represents natural oil. Composition is enclosed in gelatine capsule. Method of teeth cleaning includes application on teeth of composition for oral cavity care in such a way that composition for oral cavity care cleans teeth. Device for oral cavity care, which contains: handle, fastened on handle head, where head has external surface and a row of teeth-cleaning elements, projecting outwards on external surface, and gelatine capsule, which contains composition for oral cavity care, located on head.

EFFECT: group of inventions makes it possible to increase teeth cleaning efficiency.

14 cl, 2 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to the encapsulation of active ingredients and to processing textile materials. Claimed are: a method of processing textile materials, containing microcapsules of active ingredients, fibres and/or textile materials, obtained from the said method, and their cosmetic or pharmaceutical application and/or their application as a repellent.

EFFECT: claimed invention makes it possible to increase the active ingredient stability for an acceptable number of washings.

16 cl, 6 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to application of composition, which contains Polygonum aviculare grass 20-25 wt %, cowberry leaves 13-17 wt %, Viburnum sargentii koehne fruits 5-9 wt %, fruits of dog-rose of different of Far-East species 20-25 wt %, Schisandra chinensis seeds 13-17 wt %, Fragaria orientalis leaves 5-9 wt % and corn stigmas 5-9 wt %, as means with oil protective activity in treatment of glomerulonephritis.

EFFECT: invention provides positive influence on basic indices of glomerulonephritis: promotes recovery of diuresis, reduction of proteinuria, reduction of azotemia, cryoglobulinemia and level of circulating immune complexes.

2 tbl

FIELD: medicine.

SUBSTANCE: integrated therapy additionally involves administering thin-walled Capsicum annuum powder of the type paprika in a dose of 30 g with the specified selenium contents of 1 mg/kg and a capsule of alpha-tocopherol acetate in a dose of 100 mg manufactured by Lyumi, LLC (Ekaterinburg) orally during meals 3 times a day. The length of the treatment is 20 days.

EFFECT: invention enables reducing the time of the treatment, increasing its efficacy, and prolonging remission.

1 tbl, 2 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine. Described is a wet product from a non-woven material, soaked with a substance for personal hygiene, which is applied in household or for local processing for medicinal purposes. The non-woven material represents a bonded fibrous cloth, possessing hydrophilic properties, or a fibrous cloth, to which hydrophilic properties have been applied by processing with moisturising additives.

EFFECT: wet product possesses the high absorbing property and increased ability of releasing a substance, possessing the absorbing ability, and its transfer onto the surface.

21 cl, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to dentistry, namely represents an encapsulated oral care composition and an oral care device. According to the invention, the composition contains: (a) a gelatine capsule; and (b) an oral care composition inside the capsule and containing: (i) a hydrophilic active ingredient, (ii) a hydrophobic structuring ingredient, and (iii) an oil carrier. The hydrophilic active ingredient preferentially represents cetylpyridinium chloride. The hydrophobic structuring ingredient preferentially represents gelated mineral oil.

EFFECT: developing the composition according to the invention solves the problem of cetylpyridinium chloride migration and fish-eye capsule defect.

9 cl, 1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapeutic dentistry, and can be used for the local treatment of chronic gingivitis caused by tobacco smoking in young individuals. That is ensured by a preparatory procedure of luminal-dependent chemiluminescence of the oral fluid aiming at a maximum burst and a glow light sum. If the maximum burst falls within the range of 3.3 to 18.15 standard units, whereas the glow light sum ranges from 8.2 to 40 standard units, an antioxidant therapy is conducted by using a transverse gingival mucosa electrophoresis on 5% aqueous propolis by means of jaw electrodes in a tray at a current intensity of 0.5-1 mA and an exposure of 8-10 minutes. A polarity is alternated with a positive pole to be taken the first. The therapeutic course makes 4 procedures every second day. Colgate Propolis Toothpase and Mouthwash are used additionally during 30 days. If the maximum burst is from 0.8 to 1.24 standard units, whereas the glow light sum ranges from 3.34 to 7.5 standard units, a pro-oxidant therapy is required by using an exposure to magnetic infrared laser (MIL) light covering a projection of gums and generated by Optodan laser with a periodontal attachment The exposure parameters: 2-2,000 Hz in segments, 2 minutes per each segment, no more than 12 minutes per 1 procedure. The therapeutic course makes 4 procedures every second day. Parodontax Toothpase and Mouthwash are used additionally during 12 days.

EFFECT: method simplifies and reduces the length of the treatment in the given category of patients.

2 ex

Up!